$BTAX
Biostax Corp.

2021 Q3 Form 10-Q Financial Statement

#000149315221028066 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $114.6K $130.9K
YoY Change -12.46% -66.35%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $160.00
YoY Change -100.0% -48.39%
% of Gross Profit
Operating Expenses $0.00 $0.00
YoY Change -100.0%
Operating Profit -$114.6K
YoY Change
Interest Expense -$32.20K $893.2K
YoY Change -103.61% -261.72%
% of Operating Profit
Other Income/Expense, Net $2.657M
YoY Change
Pretax Income $3.113M $4.094M
YoY Change -23.97% -534.89%
Income Tax
% Of Pretax Income
Net Earnings $3.113M $4.094M
YoY Change -23.97% -534.89%
Net Earnings / Revenue
Basic Earnings Per Share $6.44
Diluted Earnings Per Share $239.6K $8.948M
COMMON SHARES
Basic Shares Outstanding 483.7K shares
Diluted Shares Outstanding 12.99M shares

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.686M $30.94K
YoY Change 8580.87% 378.95%
Cash & Equivalents $29.36K
Short-Term Investments $2.657M
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.686M $30.94K
YoY Change 8580.87% 378.95%
LONG-TERM ASSETS
Property, Plant & Equipment $210.00
YoY Change -88.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $200.00
YoY Change -100.0% 0.0%
Total Long-Term Assets $0.00 $410.00
YoY Change -100.0% -79.19%
TOTAL ASSETS
Total Short-Term Assets $2.686M $30.94K
Total Long-Term Assets $0.00 $410.00
Total Assets $2.686M $31.35K
YoY Change 8467.34% 271.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.183M $2.813M
YoY Change -22.39% 23.64%
Accrued Expenses $4.135M $4.509M
YoY Change -8.3% 6.46%
Deferred Revenue
YoY Change
Short-Term Debt $3.872M $2.938M
YoY Change 31.78%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.43M $11.22M
YoY Change -7.06% -16.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $10.43M $11.22M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $10.43M $11.22M
YoY Change -7.06% -16.75%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.744M -$11.19M
YoY Change
Total Liabilities & Shareholders Equity $2.686M $31.35K
YoY Change 8467.34% 271.89%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $3.113M $4.094M
YoY Change -23.97% -534.89%
Depreciation, Depletion And Amortization $0.00 $160.00
YoY Change -100.0% -48.39%
Cash From Operating Activities -$93.86K -$67.33K
YoY Change 39.4% 350.67%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 53.00K
YoY Change 88.68%
NET CHANGE
Cash From Operating Activities -93.86K -67.33K
Cash From Investing Activities
Cash From Financing Activities 100.0K 53.00K
Net Change In Cash 6.140K -14.33K
YoY Change -142.85% -4.08%
FREE CASH FLOW
Cash From Operating Activities -$93.86K -$67.33K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
USD
CY2021Q3 us-gaap Deposits Assets
DepositsAssets
USD
CY2020Q4 IMUN Undocumented Investor Advances Current
UndocumentedInvestorAdvancesCurrent
USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
USD
CY2021Q3 IMUN Financecharges
Financecharges
USD
IMUN Financecharges
Financecharges
USD
CY2020Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
USD
CY2020Q3 IMUN Gain Loss On Market Value Of Common Shares
GainLossOnMarketValueOfCommonShares
USD
IMUN Gain Loss On Market Value Of Common Shares
GainLossOnMarketValueOfCommonShares
USD
IMUN Effect Of Fractional Shares Upon Reverse Stock Split
EffectOfFractionalSharesUponReverseStockSplit
USD
us-gaap Depreciation
Depreciation
USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
USD
IMUN Gain Loss On Market Value Of Common Shares
GainLossOnMarketValueOfCommonShares
USD
IMUN Financecharges
Financecharges
USD
IMUN Increase Decrease In Deposit
IncreaseDecreaseInDeposit
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
IMUN Conversion Of Debt And Accrued Interest To Common Stock
ConversionOfDebtAndAccruedInterestToCommonStock
USD
IMUN Reclassification To Notes Payable From Accrued Interest
ReclassificationToNotesPayableFromAccruedInterest
USD
IMUN Debt Discount On Notes Payable And Warrant
DebtDiscountOnNotesPayableAndWarrant
USD
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
USD
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
USD
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
IMUN Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodExercisePrice
IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAveragePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
IMUN Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice

Files In Submission

Name View Source Status
0001493152-21-028066-index-headers.html Edgar Link pending
0001493152-21-028066-index.html Edgar Link pending
0001493152-21-028066.txt Edgar Link pending
0001493152-21-028066-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
imun-20210930.xsd Edgar Link pending
imun-20210930_cal.xml Edgar Link unprocessable
imun-20210930_def.xml Edgar Link unprocessable
imun-20210930_lab.xml Edgar Link unprocessable
imun-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending